A panel of industry leaders emphasize the importance of early engagement with payers, real-world evidence, and value-based ...

Canalevia® (crofelemer delayed-release tablets), under the name Canalevia-CA1, is conditionally approved by the FDA for ...

Domestic private pharma companies are expecting robust industry legal changes to facilitate future initiatives.